# Deceptive clinical course of mucinous ovarian carcinoma mimicking pelvic abscess in a postmenopausal woman: An exceptional case report

**Authors:** Aparna Jarathi, Sunitha Geddada, Chandramouli Ramalingam, Naina Kumar, Anusha Devalla, Ashwini Pitambra, Ashutosh Rath, NagaSai Divya Kari, Uday Reddy Janke, B Surender Reddy, Ajay Kumar Kondeti

PMC · DOI: 10.18632/oncoscience.650 · 2026-03-11

## TL;DR

A rare case of mucinous ovarian cancer in a postmenopausal woman was initially mistaken for a pelvic abscess, highlighting diagnostic challenges.

## Contribution

This case report highlights the deceptive clinical presentation of mucinous ovarian carcinoma in postmenopausal women.

## Key findings

- Mucinous ovarian carcinoma can mimic a pelvic abscess, leading to delayed diagnosis.
- Persistent symptoms and elevated tumor markers prompted further investigation and correct diagnosis.
- Multidisciplinary evaluation is crucial for accurate diagnosis and timely treatment.

## Abstract

Background: Mucinous ovarian carcinoma (MOC) is a rare subtype of epithelial ovarian cancer (3–5%), typically affecting women between 20 and 40 years old. It often presents diagnostic and management challenges.

Case Report: We present an exceptional case of a postmenopausal woman with abdominal pain disguised as a pelvic abscess. A 73-year-old postmenopausal woman presented with abdominal pain for 6 months and postmenopausal spotting for 1 month. Initial imaging (CT scan) suggested a pelvic abscess, which was managed conservatively. However, persistent symptoms and a complex adnexal mass prompted further evaluation. MRI revealed a multiloculated right adnexal mass, and tumour markers (CA-125, CEA, HE4) were elevated. Surgical staging included total abdominal hysterectomy, bilateral salpingo-oophorectomy, and omentectomy. Histopathology confirmed stage IC2 mucinous adenocarcinoma. Postoperative recovery was uneventful, and the patient received six cycles of carboplatin and paclitaxel as adjuvant chemotherapy.

Conclusions: This case emphasizes the diagnostic challenge of MOC in postmenopausal women.

Misinterpretation as benign pelvic pathology can delay appropriate treatment. Precise imaging, tumour markers, and a multidisciplinary approach are critical for early diagnosis and improved outcomes.

## Linked entities

- **Chemicals:** carboplatin (PubChem CID 426756), paclitaxel (PubChem CID 36314)
- **Diseases:** epithelial ovarian cancer (MONDO:0005140)

## Full-text entities

- **Genes:** CEACAM3 (CEA cell adhesion molecule 3) [NCBI Gene 1084] {aka CD66D, CEA, CGM1, CGM1a, W264, W282}, MUC16 (mucin 16, cell surface associated) [NCBI Gene 94025] {aka CA125}, WFDC2 (WAP four-disulfide core domain 2) [NCBI Gene 10406] {aka BENP, EDDM4, HE4, WAP5, dJ461P17.6}
- **Diseases:** tumour (MESH:D009369), pelvic abscess (MESH:D000038), abdominal pain (MESH:D015746), MOC (MESH:D010051), epithelial ovarian cancer (MESH:D000077216), mucinous adenocarcinoma (MESH:D002288)
- **Chemicals:** paclitaxel (MESH:D017239), carboplatin (MESH:D016190)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12998691/full.md

---
Source: https://tomesphere.com/paper/PMC12998691